Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age
Journal
The Journal of infectious diseases
Journal Volume
227
Journal Issue
11
Date Issued
2023-05-29
Author(s)
Díez-Domingo, Javier
Sáez-Llorens, Xavier
Rodriguez-Weber, Miguel A
Epalza, Cristina
Chatterjee, Archana
Chiu, Cheng-Hsun
Lin, Chien-Yu
Berry, Andrea A
Martinón-Torres, Federico
Baquero-Artigao, Fernando
Langley, Joanne M
Ramos Amador, José T
Domachowske, Joseph B
Chiu, Nan-Chang
Esposito, Susanna
Moris, Philippe
Lien-Anh Nguyen, Thi
Nikic, Vanja
Woo, Wayne
Zhou, Yingjun
Dieussaert, Ilse
Leach, Amanda
Gonzalez Lopez, Antonio
Vanhoutte, Nicolas
Abstract
Safe and effective respiratory syncytial virus (RSV) vaccines remain elusive. This was a phase I/II trial (NCT02927873) of ChAd155-RSV, an investigational chimpanzee adenovirus-RSV vaccine expressing 3 proteins (fusion, nucleoprotein, and M2-1), administered to 12-23-month-old RSV-seropositive children followed up for 2 years after vaccination.
Subjects
immunogenicity; neutralizing antibodies; respiratory syncytial virus; safety; vaccine
SDGs
Type
journal article